Sutrix, a two-person startup in Y Combinator's Fall 2026 batch, has launched a platform that prepares healthcare providers' clinical records for licensing to pharmaceutical companies and AI laboratories, according to the company's website and its YC launch page. The company's only disclosed revenue, however, comes from a different business.
Sutrix says it reached $20,000 in monthly recurring revenue within two months by helping research teams prepare patient data for studies. It has not shown that any of that money came from licensing.
What the product does
The licensing offering is aimed at health systems and other providers. "No software fees," Sutrix's website says. "Your organization receives a share of revenue from approved data licenses."
The company says links back to original provider records allow later outcomes and additional clinical detail to be added to a dataset. YC's launch page describes the licensing product as an extension of Sutrix's research-data software.
Absent from the public materials are revenue-share percentages, minimum guarantees, exclusivity terms, contract length and dataset pricing. Nor do they include a de-identification methodology or an independent privacy assessment.
Where the traction came from

"We reached $20k MRR within two months, helping research teams continuously prepare patient data for their studies," the company wrote on its YC launch page. The same figure appears on its YC company profile. When it was measured is not disclosed.
A LinkedIn post by co-founder Supratik Panuganti offered a bigger number: 15-plus labs, 50-plus studies and more than $150,000 in revenue over "the past few months." That total is cumulative rather than monthly, and the post does not separate software from services, state the recognition period or describe customer concentration (how much of the revenue rests on a few clients).
"We've been using this software to run those studies, getting faster and improving quality with each one," Panuganti wrote.

